Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 2, 2007, Pages 65-71

  Palaparthy, Rameshraja ^a,c   Pradhan, Rajendra S ^a   Chan, Jenny ^a   Rieser, Matthew ^a   Chira, Titus ^a   Galitz, Lawrence ^b   Awni, Walid ^a   Williams, Laura A ^a  

^a ABBOTT LABORATORIES   (United States)

^b South Florida Bioavailability Clinic   (United States)

^c Department R4PK ^*  (United States)

Author keywords

Drug interaction; Kidney disease; Pharmacokinetics; Proton pump inhibitors; Vitamin D; Zemplar

Indexed keywords

OMEPRAZOLE; PARICALCITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ERGOCALCIFEROLS; FEMALE; GASTRIC ACIDITY DETERMINATION; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 33947425204     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.532     Document Type: Article

References (14)

1. Pradhan R, Daszkowski D, Zhang Y, Chen P, O'Dea R, Qiu P. Assessment of the absolute bioavailability and food effect of paricalcitol capsule (Zemplar™) in healthy adults. J Am Soc Nephrol 2001; 12: 770A.
2. Pradhan R, Daszkowski D, Zhang Y, Chen P, O'Dea R, Qiu P. Assessment of dose proportionality of paricalcitol capsule (Zemplar™) in healthy adults. J Am Soc Nephrol 2001; 12: 770A.
3. Palaparthy R, Pradhan R, McNeill D, Williams L, O'Dea R. Single and multiple dose safety and pharmacokinetic assessment of paricalcitol (Zemplar®) capsule following daily (qd) and three-times-a-week dosing in healthy subjects. Am J Kidney Dis 2004; 4: A35: 81.
4. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993; 38: 257-268.
5. el-Lakany S, Eagon PK, Gavaler JS, Schade RR, Whiteside T, Van Thiel DH. Gastrointestinal function, morphology, and immune status in uremia. Nutrition 1990; 6: 461-468.
6. Watanabe H, Hiraishi H, Ishida M, Kazama JJ, Terano A. Pathophysiology of gastric acid secretion in patients with chronic renal failure: influence of Helicobacter pylori infection. J Intern Med 2003; 254: 439-446.
7. Ventkateswaran PS, Jeffers A, Hocken AG. Gastric acid secretion in chronic renal failure. Br Med J 1972; 4: 22-23.
8. Prilosec (omeprazole) Package Insert (Label) Astra Zeneca Inc. http://www.astrazeneca-us.com/pi/prilosec/plcoated.pdf.
9. Soons PA, van den Berg G, Danhof M, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42: 319-324.
10. Negro RD. Pharmacokinetic drug interactions with anti-ulcer drugs. Clin Pharmacokinet 1998; 35: 135-150.
11. Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69: 266-273.
12. Rost KL, Fuhr U, Thomsen T, et al. Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharmacol Ther 1999; 37: 567-574.
13. Coding Symbols for Thesaurus of Adverse Reaction Terms, 5th edn. Department of Health and Human Services, Food and Drug Administration.
14. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212.